A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 466 participants.
Also called NCT01582451
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 466 participants
- Sponsor
- Registry
-
NCT01582451
-
- Other papers using this trial's data
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Germany, Greece, Israel, Puerto Rico, Romania, Russia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01582451. Randomized; no masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2018-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
- Acronym
- IMAGINE 5
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LY2605541
- Intervention (Drug)
- Insulin glargine
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01582451- Content hash
13c4e9fcbfaf9471fb4cc5123fdc520a046dc01db85a33f66122ea187c729c3d